TABLE 1.

Anti-cancer agent interaction with COVID-19 agent.

Anti-cancer agent	Interaction with anti-COVID-19 agent	Mechanism	Effect
Regorafenib	Azithromycin	Multikinase inhibitor specially inhibits tyrosine kinase	Reduction in therapeutic potential
Vinblastin	Azithromycin	Inhibition of mitosis leading to cell death	P-glycoprotein serum levels are increased
Doxorubicin	Chloroquine	Inhibition of topoisomerase II and initiation of apoptosis	Cardiac related abnormalities
Trastuzumab	Chloroquine	Inhibition of HER2	Cardiac related abnormalities
Fluorouracil	Anakinra	Inhibition of thymidylate synthase	Suppression of immunity
Fluorouracil	Tocilizumab	Inhibition of thymidylate synthase	Suppression of immunity
Durvalumab	Anakinra	Inhibition of PD-L1	Reduced therapeutic efficacy
Enzalutamide	Favipiravir	Competitive binding of androgen, inhibition of tumor gene transcription	Reduction in action of antiviral agent
Abiraterone	Tocilizumab	Androgen biosynthesis inhibitor	Tocilizumab reduced abiraterone as CYP3A4 inducer
Abiraterone	Colchicine	Androgen biosynthesis inhibitor	Increase action of abiraterone as CYP3A4 inhibitor
Docetexel	Tocilizumab	Inhibition of microtubular depolymerization	Tocilizumab reduced docetexel as CYP3A4 inducer
Ruxolitinib	Tocilizumab	Inhibits myelofibrosis and JAK	Tocilizumab reduced ruxolitinib as CYP3A4 inducer
Paclitaxel	Tocilizumab	Inhibits cell division by altering chromosomal segregation	Tocilizumab reduced paclitaxel as CYP3A4 inducer